Paul Gitman Net Worth

The estimated Net Worth of Paul Gitman is at least $6.46 million dollars as of 15 May 2019. Paul Gitman owns over 5,000 units of Biospecifics Technologies stock worth over $1,327,950 and over the last 15 years he sold BSTC stock worth over $4,927,501. In addition, he makes $202,507 as Independent Director at Biospecifics Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Gitman BSTC stock SEC Form 4 insiders trading

Paul has made over 24 trades of the Biospecifics Technologies stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of BSTC stock worth $329,150 on 15 May 2019.

The largest trade he's ever made was exercising 36,308 units of Biospecifics Technologies stock on 23 June 2015 worth over $782,074. On average, Paul trades about 11,103 units every 126 days since 2009. As of 15 May 2019 he still owns at least 15,000 units of Biospecifics Technologies stock.

You can see the complete history of Paul Gitman stock trades at the bottom of the page.

Paul Gitman biography

Dr. Paul A. Gitman M.D. serves as Independent Director of the Company. He is board certified by the American Board of Internal Medicine, the American Board of Medical Quality and the American Board of Quality Assurance and Utilization Review. Dr. Gitman is a Master in the American College of Physicians. Following 25 years in private medical practice in internal medicine, he joined the fulltime faculty of Long Island Jewish Medical Center where he eventually became Medical Director. Dr. Gitman then transitioned to a health system role, serving as the Vice President of Medical Affairs for the North Shore Long Island Jewish Health System (Northwell Health) until 2009 when he retired. Since that time, Dr. Gitman has been a private consultant in Quality Improvement. Dr. Gitman is currently an Associate Professor of Medicine at The Hofstra North Shore LIJ School of Medicine. Previously, he served as Chairman of the Medical Society of the State of New York’s Committee for Physician’s Health. He served on the New York State Board of Medicine for 10 years and on various New York State Committees and Task Forces. He is the past President of The American College of Medical Quality, the New York Chapter of the American College of Physicians and the Medical Society of the County of Queens. Dr. Gitman received his medical degree from Boston University School of Medicine. Dr. Gitman was a Major in the United States Air Force. The Company believes that Dr. Gitman is qualified to serve as a member of our Board due to his extensive medical background and professional experience.

What is the salary of Paul Gitman?

As the Independent Director of Biospecifics Technologies, the total compensation of Paul Gitman at Biospecifics Technologies is $202,507. There are 1 executives at Biospecifics Technologies getting paid more, with Jennifer Chao having the highest compensation of $217,507.

How old is Paul Gitman?

Paul Gitman is 79, he's been the Independent Director of Biospecifics Technologies since 1990. There are 2 older and 6 younger executives at Biospecifics Technologies. The oldest executive at Biospecifics Technologies Corp. is Toby Wegman, 85, who is the Director.

What's Paul Gitman's mailing address?

Paul's mailing address filed with the SEC is C/O BIOSPECIFICS TECHNOLOGIES CORP., 2 RIGHTER PKWY, DE CORP CENTER II, WILMINGTON, DE, 19803.

Insiders trading at Biospecifics Technologies

Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo et Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.

What does Biospecifics Technologies do?

Complete history of Paul Gitman stock trades at Biospecifics Technologies

Biospecifics Technologies executives and stock owners

Biospecifics Technologies executives and other stock owners filed with the SEC include:

• Jennifer Chao,
  Independent Chairman of the Board
• Michael Schamroth,
  Independent Director
• Paul Gitman,
  Independent Director
• Mark Wegman,
  Director
• Toby Wegman,
  Director
• Sarah McCabe,
  Stern Investor Relations
• Michael Sherman,
  Independent Director
• Corey Fishman,
  Independent Director
• Alex Monteith,
  Senior Vice President and Chief Business Officer
• Patrick Hutchison,
  Chief Financial Officer
• Joseph Truitt,
  Chief Executive Officer, Director
• Jeffrey Kenneth Vogel,
  
• Jyrki Mattila,
  Director
• Thomas Wegman,
  President
• Of Edwin H. Wegman Estate,
  10% owner
• Patrick M Caldwell,
  Principal Financial Officer
• Partners Lp Bio,
  10% owner
• Albert Horcher,
  
• Lawrence Dobroff,
  CFO
• Max Link,
  Director
• Henry Morgan,
  Director
• George M Gould,
  Director
• Matthew Geller,
  Director
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• Capital Management, Llcaldr...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• J Kevin Buchi,
  Chief Executive Officer
• International Plc Endo,
  10% owner